Key Takeaways
- Novartis has announced job cuts within its Biomedical Research organization amid ongoing staff consolidations.
- The company aims to treat affected employees with fairness and respect as it makes these strategic adjustments.
- This downsizing follows previous reductions, including a recent closure of a facility in Germany that will eliminate around 220 jobs.
Job Cuts Confirmed at Novartis
Recently, Novartis confirmed a new round of job cuts primarily affecting its Biomedical Research division. This news follows speculation about layoffs circulating on social media. A company spokesperson stated that individual impacts have been communicated to a select group of employees, acknowledging the difficulty of the situation.
Novartis, which employed approximately 5,720 professionals in its biomedical research department as of the end of 2025, has multiple research sites, including locations in Basel, Switzerland; Cambridge, Massachusetts; East Hanover, New Jersey; and California (San Diego and Emeryville).
This latest downsizing is not an isolated event. Novartis has made several adjustments to its research-focused operations in recent years. In 2024, the company signaled a “phased exit” from its Technical Research and Development site in San Diego, affecting about 100 employees at that time.
In addition to the recent job cuts, Novartis is undergoing a broader multi-year restructuring that has seen reductions in various roles, particularly those connected to its New Jersey headquarters. Earlier this month, the company announced plans to close a production facility in Wehr, Germany, which is primarily involved with older drugs. This closure is expected to result in around 220 job losses and is part of a larger strategy that includes shuttering the site by the end of 2028.
Overall, Novartis is navigating a challenging landscape as it continues to adapt its workforce and organizational structure in response to strategic priorities and market conditions.
The content above is a summary. For more details, see the source article.